120 related articles for article (PubMed ID: 38644999)
1. Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy.
Hulse J; Maphis N; Peabody J; Chackerian B; Bhaskar K
bioRxiv; 2024 Apr; ():. PubMed ID: 38644999
[TBL] [Abstract][Full Text] [Related]
2. Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy.
Maphis NM; Peabody J; Crossey E; Jiang S; Jamaleddin Ahmad FA; Alvarez M; Mansoor SK; Yaney A; Yang Y; Sillerud LO; Wilson CM; Selwyn R; Brigman JL; Cannon JL; Peabody DS; Chackerian B; Bhaskar K
NPJ Vaccines; 2019; 4():26. PubMed ID: 31231552
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies.
Hart de Ruyter FJ; Morrema THJ; den Haan J; ; Twisk JWR; de Boer JF; Scheltens P; Boon BDC; Thal DR; Rozemuller AJ; Verbraak FD; Bouwman FH; Hoozemans JJM
Acta Neuropathol; 2023 Feb; 145(2):197-218. PubMed ID: 36480077
[TBL] [Abstract][Full Text] [Related]
6. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
7. Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology.
Hartnell IJ; Woodhouse D; Jasper W; Mason L; Marwaha P; Graffeuil M; Lau LC; Norman JL; Chatelet DS; Buee L; Nicoll JAR; Blum D; Dorothee G; Boche D
Brain; 2024 Feb; 147(2):590-606. PubMed ID: 37703311
[TBL] [Abstract][Full Text] [Related]
8. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
9. Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons.
Burack MA; Halpain S
Neuroscience; 1996 May; 72(1):167-84. PubMed ID: 8730715
[TBL] [Abstract][Full Text] [Related]
10. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
11. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
12. Structures of AT8 and PHF1 phosphomimetic tau: Insights into the posttranslational modification code of tau aggregation.
Mammeri NE; Dregni AJ; Duan P; Hong M
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2316175121. PubMed ID: 38408247
[TBL] [Abstract][Full Text] [Related]
13. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro.
Shin RW; Lee VM; Trojanowski JQ
J Neurosci; 1994 Nov; 14(11 Pt 2):7221-33. PubMed ID: 7525898
[TBL] [Abstract][Full Text] [Related]
14. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
Huber CM; Yee C; May T; Dhanala A; Mitchell CS
J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
[TBL] [Abstract][Full Text] [Related]
15. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
16. Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421.
Cao L; Liang Y; Liu Y; Xu Y; Wan W; Zhu C
Exp Cell Res; 2018 Sep; 370(1):103-115. PubMed ID: 29908160
[TBL] [Abstract][Full Text] [Related]
17. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
18. Visual Evoked Potentials as an Early-Stage Biomarker in the rTg4510 Tauopathy Mouse Model.
Parka A; Volbracht C; Hall B; Bastlund JF; Nedergaard M; Laursen B; Botta P; Sotty F
J Alzheimers Dis; 2023; 93(1):247-262. PubMed ID: 37005884
[TBL] [Abstract][Full Text] [Related]
19. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
20. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
